A review of the actionable news that came out of last week’s American College of Cardiology conference in San Francisco, including mixed feelings about Boston Scientific’s Watchman stroke prevention device and incremental findings for renal denervation.
Sometimes the major annual medical meetings are jam-packed with significant and market-moving data. And then sometimes they’re like this year’s American College of Cardiology conference, with relatively limited useful data from an investing perspective.
While there was some incremental data relating to significant emerging growth markets like transcatheter valve replacement and renal denervation, the most significant data concerns one of the more uncertain market opportunities – left atrial appendage occlusion/closure.
